Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14089 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Lucas C Zarling und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, Washington, DC, USA. Hauptthemen laut MEDLINE: Doxorubicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Objectives
We recently performed a single‐arm phase II trial of DA‐EPOCH in adults with acute lymphoblastic leukemia (ALL). We sought to compare these results to those with standard Hyper‐CVAD.
Methods
We created a retrospective matched cohort of patients who received Hyper‐CVAD ( n = 69) at our center and otherwise met eligibility criteria for the DA‐EPOCH trial ( n = 53).
Results
Our outcomes support the use of Hyper‐CVAD over DA‐EPOCH in Ph− disease for both overall survival (OS; HR 0.18, p = .004) and event‐free survival (EFS; HR 0.51, p = .06). In contrast, outcomes were similar in Ph+ disease (OS HR 0.97, p = .96; EFS HR 0.65, p = .21). Rates of morphologic remission and measurable residual‐disease negativity were similar between the regimens. Hyper‐CVAD was associated with significantly more febrile neutropenia (OR 1.9, p = .03) and a greater incidence of Grade 4 or 5 adverse events (20% vs. 6%). Average transfusions per cycle of both red blood cells ( p < .001) and platelets ( p < .001) were five‐fold higher with Hyper‐CVAD.
Conclusions
Our findings support continued use of Hyper‐CVAD for Ph− ALL but suggest that DA‐EPOCH may be a reasonable alternative for Ph+ ALL. These data also highlight a potential role for DA‐EPOCH in resource‐limited settings or when more intense therapy is not feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Washington, Seattle, Washington, DC, USA.
- Clinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
- Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
ORCID-Profile: Lucas C Zarling, Jason P Cooper
Zitieren
APA
Zarling, L. C., Stevenson, P. A., Soma, L. A., Martino, C. H., Percival, M. M., Halpern, A. B., Ghiuzeli, C. M., Becker, P. S., Oehler, V. G., Cooper, J. P., Orozco, J. J., Hendrie, P. C., Walter, R. B., Estey, E. H., & Cassaday, R. D. (2023). Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14089
Vancouver
Zarling LC, Stevenson PA, Soma LA, Martino CH, Percival MM, Halpern AB, et al. Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia. European Journal of Haematology. 2023. doi:10.1111/ejh.14089
BibTeX
@article{Zarling2023,
author = {Zarling, Lucas C and Stevenson, Philip A and Soma, Lorinda A and Martino, Christen H and Percival, Mary-Elizabeth M and Halpern, Anna B and Ghiuzeli, Cristina M and Becker, Pamela S and Oehler, Vivian G and Cooper, Jason P and Orozco, Johnnie J and Hendrie, Paul C and Walter, Roland B and Estey, Elihu H and Cassaday, Ryan D},
title = {Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14089}
}
EUVIMED